X4 Pharmaceuticals

X4 Pharmaceuticals(XFOR)

BOSTON, MA
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: Oral small molecules

X4 Pharmaceuticals is a life sciences company focused on Oral small molecules.

Neurology
Funding Stage
PUBLIC
Open Jobs
1

Pipeline & Clinical Trials

No intervention
WHIM Syndrome
N/A
Clinical Trials (1)
NCT03087370A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
N/A
X4P-001
Healthy
Phase 1
Clinical Trials (1)
NCT02680782A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT06914869Drug-Drug Interaction Potential of Mavorixafor
Phase 1
Phase 1
Clinical Trials (1)
NCT04274738A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Phase 1
X4P-001
Melanoma
Phase 1
Clinical Trials (1)
NCT02823405X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
Phase 1
Phase 1
Clinical Trials (1)
NCT06858696A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
Phase 1
Phase 1/2
Clinical Trials (1)
NCT02667886Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02923531Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
Phase 1/2
Mavorixafor
Neutropenia
Phase 1/2
Clinical Trials (1)
NCT04154488A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
Phase 1/2
Phase 2
Clinical Trials (1)
NCT03005327A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Phase 2
Mavorixafor
Neutropenia
Phase 3
Clinical Trials (1)
NCT06056297A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Phase 3
Mavorixafor
WHIM Syndrome
Phase 3
Clinical Trials (1)
NCT03995108Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Phase 3

Open Jobs (1)

Senior Accountant

Boston, MA, US
2mo ago
$85K - $100K/yr
Interview Prep Quick Facts
Founded: 2013
Portfolio: 12 clinical trials
SEC Filings: 2 available
Open Roles: 1 active job

Financials (FY2024)

Revenue
$0
R&D Spend
$61M21%
Net Income
-$94M
Cash
$122M
Source: SEC 10-K Filing

Hiring Trend

Stable
1
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles